资讯

Truce talks start between Thailand and Cambodia in Malaysia Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and ...
KRAS 是人类恶性肿瘤中突变率最高的致癌基因之一,常见于胰腺癌 (约 80%)、结直肠癌 (约 40%)和肺癌 (约 30%)。 其以单碱基错义突变为主,超 80% 发生在第 12 号密码子 (G12),包括 G12C、G12D 和 G12V ...
近日,艾伯维斥资7亿美元预付款,引进IGI Therapeutics SA(IGI)公司的三特异性抗体新药ISB 2001,在北美、欧洲、日本和大中华区开发、制造和商业化的独家权利。根据协议,IGI将获得7亿美元的预付款,并有资格获得高达12.25亿美元的开发、监管和商业里程碑付款,以及分层的两位数净销售额特许权使用费。
T细胞衔接器(T Cell Engager, TCE)是一种双特异性或多特异性抗体,可以同时靶向肿瘤相关细胞表面抗原(Tumor-Associated Antigen,TAA)和T细胞表面受体(T-Cell ...
The multi-target collaboration combines the respective expertise of each company with Medigene’s 3S (sensitive, specific and safe) TCR generation and characterization capabilities and EpimAb’s ...
The multi-target collaboration combines the respective expertise of each company with Medigene’s 3S (sensitive, specific and safe) TCR generation and characterization capabilities and EpimAb’s ...
TCR-TCEs are designed to bind the TCR via a target and redirect the patient's T cells, which are then activated by the anti-CD3 monoclonal antibody, leading to release of cytokines and cytotoxic ...
High TCR-CD3 stimulation facilitates the induction of IL-21-expressing Tfh-like cells We examined the impact of T cell receptor (TCR) stimulation strength on naive CD4 + T cell differentiation into IL ...
This suggests an absence of ‘inactive-active’ conformational states in the TCR constant regions and the extracellular CD3 subunits, unlike the transmembrane regions of the complex. This study ...